0A3S Stock Overview
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Novavax, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.51 |
52 Week High | US$11.32 |
52 Week Low | US$3.53 |
Beta | 1.6 |
1 Month Change | -5.70% |
3 Month Change | 10.56% |
1 Year Change | -36.62% |
3 Year Change | -97.59% |
5 Year Change | -55.83% |
Change since IPO | -86.07% |
Recent News & Updates
Recent updates
Shareholder Returns
0A3S | GB Biotechs | GB Market | |
---|---|---|---|
7D | 8.5% | 3.8% | 1.2% |
1Y | -36.6% | -25.7% | 2.3% |
Return vs Industry: 0A3S underperformed the UK Biotechs industry which returned -25.7% over the past year.
Return vs Market: 0A3S underperformed the UK Market which returned 2.3% over the past year.
Price Volatility
0A3S volatility | |
---|---|
0A3S Average Weekly Movement | 13.9% |
Biotechs Industry Average Movement | 7.3% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.4% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0A3S's share price has been volatile over the past 3 months.
Volatility Over Time: 0A3S's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 1,543 | John Jacobs | www.novavax.com |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
Novavax, Inc. Fundamentals Summary
0A3S fundamental statistics | |
---|---|
Market cap | US$603.61m |
Earnings (TTM) | -US$545.06m |
Revenue (TTM) | US$983.71m |
0.7x
P/S Ratio-1.2x
P/E RatioIs 0A3S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0A3S income statement (TTM) | |
---|---|
Revenue | US$983.71m |
Cost of Revenue | US$1.08b |
Gross Profit | -US$94.76m |
Other Expenses | US$450.30m |
Earnings | -US$545.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.91 |
Gross Margin | -9.63% |
Net Profit Margin | -55.41% |
Debt/Equity Ratio | -23.4% |
How did 0A3S perform over the long term?
See historical performance and comparison